While the pharma industry has delivered many essential medicines, a consequence of attrition in pharmaceutical R&D is that many compounds that are tested in clinical trials never become medicines. Quite often compounds that seem safe in clinical trials are not selected to move forward and could become shelved. Sometimes these compounds have potential utility in the original or other indications, but are commercially unviable or off-strategy for the originating company.
SpringWorks was formed by Pfizer, Bain Capital, Orbimed and LifeArc and is one approach to address this dilemma. Working with foundations and others, SpringWorks will leverage its novel structure to revitalize ‘shelved’ compounds to deliver new therapies to patients underserved by existing treatments. In this panel, learn about the path to the creation of SpringWorks, its novel approach to drug development and several other approaches to breathing new life into neglected compounds.

Ability Level: All

Session ID: 21089